Palbociclib (orotate)
Palbociclib (PD 0332991) orotate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib orotate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib orotate can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma[1][3][4].
Product Specifications
CAS Number
2757498-64-7
Product Name Alternative
PD 0332991 (orotate)
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/palbociclib-orotate.html
Solubility
10 mM in DMSO
Smiles
O=C1C(C(C)=O)=C(C2=CN=C(N=C2N1C3CCCC3)NC4=CC=C(N5CCNCC5)C=N4)C.O=C6C=C(C(O)=O)NC(N6)=O
Molecular Formula
C29H33N9O6
Molecular Weight
603.63
References & Citations
[1]Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3 (11) :1427-38.|[2]Goel S, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548 (7668) :471-475.|[3]Richard S Finn, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11 (5) :R77.|[4]Bollard J, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2017 Jul;66 (7) :1286-1296.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
CDK4; CDK6
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LS165918-20ug 20 µg
RNF168 (NM_152617) Human Over-expression Lysate
Sign In for Pricing
View Details